Medication info

Posimet Extended-Release Tablet 5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›7.35mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
Dark pink, bilaterally convex, egg-shaped film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202107049 · Approved 2021.10.20

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no prior experience of diabetes drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of diabetes drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin therapy, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the dose of metformin the patient was previously taking or an appropriate dose therapeutically close to it. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medication, treatment may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other glucose-lowering medications. Because changes may cause alterations in glycemic control, any change in treatment in patients with type 2 diabetes should be made with careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medication may be excreted in the stool as a soft hydrated mass resembling a tablet. Renal impairment No dosage adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication is used as a combination therapy of dapagliflozin and metformin, primarily for assisting in blood sugar control for adult patients with type 2 diabetes. It is administered as an adjunct to diet and exercise therapy for effective blood sugar management. Additionally, among patients with type 2 diabetes who do not achieve sufficient blood sugar control, especially those with cardiovascular diseases or risk factors, it is advised to consult an expert regarding the impact of dapagliflozin on the occurrence of cardiovascular events. Therefore, this medication serves as an important treatment option that aids in blood sugar control and cardiovascular health management for patients with type 2 diabetes.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no prior experience of diabetes drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of diabetes drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin therapy, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the dose of metformin the patient was previously taking or an appropriate dose therapeutically close to it. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medication, treatment may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other glucose-lowering medications. Because changes may cause alterations in glycemic control, any change in treatment in patients with type 2 diabetes should be made with careful monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medication may be excreted in the stool as a soft hydrated mass resembling a tablet. Renal impairment No dosage adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Precautions

This medication is used for the treatment of type 2 diabetes and helps lower blood sugar levels. However, it can very rarely cause a dangerous condition called severe lactic acidosis, so it should not be used in patients with poor kidney function, severe infections, dehydration, or acute heart problems. Moreover, caution is advised when taken with other diabetes medications such as insulin or sulfonylureas due to the risk of hypoglycemia. Patients with reduced kidney function, elderly patients, or those with decreased fluid volume should have their kidney function and fluid status carefully evaluated before starting this medication, and during treatment, symptoms of hypotension or changes in kidney function should be closely monitored. This medication can increase the risk of genital and urinary tract infections, so immediate treatment is required if symptoms of infection appear. It may also reduce vitamin B12 levels, so it is advisable to regularly check vitamin B12 levels during long-term use. Pregnant or breastfeeding women should not take this medication, and it is safer to discontinue it for a period before and after surgery. Excessive alcohol consumption may also increase the risk of side effects, so it should be avoided. While taking this medication, be attentive to symptoms of hypoglycemia or dehydration, and if any unusual symptoms arise, consult a doctor immediately. Finally, safety and efficacy in children have not been established, and elderly patients should have their kidney function regularly checked while adjusting the dosage.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • kidney dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignant neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • tooth pain
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • itching
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly closed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. This helps to preserve the medication's effectiveness for a long time.

Appearance and packaging

Appearance

Dark pink, bilaterally convex, egg-shaped film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.